Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/raffles-medical-group-ltd" target="_blank" data-smartkarma-citation="entities:879:1" rel="noopener">Raffles Medical (RFMD SP)</a> reported strong H1 2022 results, with double-digit growth in revenue and net profit. With the resumption of international travel, the company is seeing increasing patients.</li>
<li>While COVID-related revenue is declining, the company’s hospital business will benefit from the returning of foreign patients as well as resumption of elective surgeries for the domestic patients.</li>
<li>Raffles Medical has received the approval to set up an IVF clinic in Hainan province of China.</li>
</ul>



Raffles Medical (RFMD SP) reported strong H1 2022 results, with double-digit growth in revenue and net profit. With the resumption of international travel, the company is seeing increasing patients.
While COVID-related revenue is declining, the company’s hospital business will benefit from the returning of foreign patients as well as resumption of elective surgeries for the domestic patients.
Raffles Medical has received the approval to set up an IVF clinic in Hainan province of China.


Raffles Medical (RFMD SP): Stellar H1 Performance Driven by Resumption of Medical Tourism

<ul>
<li>
<a href="https://www.smartkarma.com/entities/raffles-medical-group-ltd" target="_blank" data-smartkarma-citation="entities:879:1" rel="noopener">Raffles Medical (RFMD SP)</a> reported 27% y/y revenue growth to S$723.8 million and net profit increase of 30% y/y to S$83.7 million in 2021.</li>
<li>Following full border reopening by Singapore beginning April, medical tourism is set to revive. As a leading hospital operator in Singapore, Raffles is well-positioned to grab the opportunity. </li>
<li>Regular share buyback and recent stake increase by a major investor further enhance conviction on the company’s growth potential.</li>
</ul>



Raffles Medical (RFMD SP) reported 27% y/y revenue growth to S$723.8 million and net profit increase of 30% y/y to S$83.7 million in 2021.
Following full border reopening by Singapore beginning April, medical tourism is set to revive. As a leading hospital operator in Singapore, Raffles is well-positioned to grab the opportunity. 
Regular share buyback and recent stake increase by a major investor further enhance conviction on the company’s growth potential.


Raffles Medical (RFMD SP): Resilient Business Model; Border Reopening to Further Boost Growth

Forensic Analyst

Jason Yap, CFA

<ul>
<li>Singapore will apply streamlined COVID-19 rules from 25 February 2022, with a focus on vaccination status instead of an aggressive testing and surveillance regime </li>
<li>We previously discussed how Raffles Medical benefits as the primary testing services provider at Changi airport and by facilitating Singapore's vaccination drive</li>
<li>Given the latest pivot in border protocols, and taking into account Singapore's high vaccination rates, we discuss whether our initial investment hypothesis remains intact</li>
</ul>


Singapore will apply streamlined COVID-19 rules from 25 February 2022, with a focus on vaccination status instead of an aggressive testing and surveillance regime 
We previously discussed how Raffles Medical benefits as the primary testing services provider at Changi airport and by facilitating Singapore's vaccination drive
Given the latest pivot in border protocols, and taking into account Singapore's high vaccination rates, we discuss whether our initial investment hypothesis remains intact


Raffles Medical (RFMD SP) - Pivot in SG Travel Rules, Testing Regime and Its Implications

Asian Insight Provider - Actionable ideas, CrossASEAN Research

Henry Soediarko

Asian Insight Provider - Actionable ideas

CrossASEAN Research

At CrossASEAN Research we strive to produce unbiased and differentiated on the ground insights on companies across South East Asia. Our Research is produced for the most part after face to face meetings and conversations with company management to dig deep into the long term vision and strategy of the companies we cover. We seek to deliver investable and actionable themes on sectors and markets across SE Asia, often in collaboration with other Insight Providers across the region, pooling the vast experience of the analysts within the Smartkarma Ecosystem. We also offer bespoke work and tailor made trips for our clients. 

Insights across South East Asia

<ul>
<li>The share price has increased by around 20% since mid-last year.</li>
<li>A new revenue stream from the booking fee through the Zig app and calls that, albeit small, it was never possible to share upside with cabbies before. </li>
<li>Extension from 15 days to 30 days visa-free for Chinese tourists to come to Singapore on early 2024. </li>
</ul>


The share price has increased by around 20% since mid-last year.
A new revenue stream from the booking fee through the Zig app and calls that, albeit small, it was never possible to share upside with cabbies before. 
Extension from 15 days to 30 days visa-free for Chinese tourists to come to Singapore on early 2024. 


Thomson Medical Group Limited / Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/thomson-medical-group-limited" target="_blank" data-smartkarma-citation="entities:8495:1" rel="noopener">Thomson Medical Group Limited (TMG SP)</a> has updated its future growth plan in Southeast Asia. The company is currently in preliminary confidential discussions to explore a potential transaction.</li>
<li>Media reports suggest, Thomson Medical is eyeing a controlling stake in Vietnam-based leading multi-specialized tertiary care provider, FV Hospital for $300–400M.  </li>
<li>Thomson Medical has a strong balance sheet, with cash reserve of S$143M, against debt of S$626M. Last month, the company has issued S$120M 5.5% notes due 2028.</li>
</ul>



Thomson Medical Group Limited (TMG SP) has updated its future growth plan in Southeast Asia. The company is currently in preliminary confidential discussions to explore a potential transaction.
Media reports suggest, Thomson Medical is eyeing a controlling stake in Vietnam-based leading multi-specialized tertiary care provider, FV Hospital for $300–400M.  
Thomson Medical has a strong balance sheet, with cash reserve of S$143M, against debt of S$626M. Last month, the company has issued S$120M 5.5% notes due 2028.


Thomson Medical Group (TMG SP): Scouting for Expansion in South East Asia

Singapore

Raffles Medical Group Limited is a health care provider.  The Company operates medical clinics, imaging centers, and medical laboratories.  Raffles provides general and specialized medical, medical evacuation, medical advisory, and dental treatment services.

Raffles Medical Group (RFMD SP)

Raffles Medical (RFMD SP): Stellar H1 Performance Driven by Resumption of Medical Tourism

Raffles Medical’s H1 revenue grew 11%, while net profit jumped 51%. Resumption of medical tourism and returning of domestic patients seeking...

Tina Banerjee

Raffles Medical (RFMD SP): Resilient Business Model; Border Reopening to Further Boost Growth

RMG’s operating performance remained resilient to the pandemic, driven by healthcare services business. Resumption of medical tourism in Singapore...

Tina Banerjee

Raffles Medical (RFMD SP) - Pivot in SG Travel Rules, Testing Regime and Its Implications

Singapore will apply streamlined COVID-19 rules from 25 Feb, with a focus on vaccination status instead of aggressive testing. We discuss whether...

Jason Yap, CFA

Comfortdelgro (CD): The Chinese Is Back

Comfortdelgro enjoys new revenue stream that allows upside participation in the number of rides, and longer visa-free stay for Chinese tourists in...

Henry Soediarko

Thomson Medical Group (TMG SP): Scouting for Expansion in South East Asia

Thomson Medical is eyeing a controlling stake in a Vietnam-based hospital. With an aging population, rapidly growing middle class, and increasing...

Tina Banerjee